This is not a very important drug at all. They will be lucky to make a profit on it. The key for ALKS is not only Bydureon but other drugs of that nature which they can assist in making patients take less frequenetly and just reaping a % of sales with no risk. That is a great deal, and that is the real potential here. I am not sure why they got ditched by J&J I think it was on that other one they were doing the same thing for, but evidently they are not the only guys on the block with this kind of product. Next up I think they may be working with Amylin for a monthly instead of weekly version of Bydureon so that will be the next time to revisit this stock I think after Bydureon gets approved.
It's no simple task developing next-gen diabetes drugs; a lesson Roche learned first-hand with its recent taspoglutide debacle. GLP-1 drugs are expected to grab a big share of the growing market, and analysts are now betting that Bydureon--a long-acting version of Byetta that is injected once a week--will be a likely star performer.
Sales estimates are all over the map, ranging from $1 billion to a heady $6 billion, demonstrating once again how hard it is to predict anything in the biopharma world. But there's considerable consensus that the three companies partnered on this program are going to come out well ahead.
This is a huge deal! Opiate addiction is getting completely out of control! Do you know how many people are hooked on opiate replacement therapies alone such as methadone and suboxone that will now have the option of taking Vivitrol? Lots! Plus you gotta wonder about a buyout of ALKS...STRONG BUY!!!!!!